Table 2.
Management during hospitalisation and outcome for all patients and prescription for survivors to discharge from hospital in STEMI according to heart failure status between MINAP and JROAD‐DPC
| Total (Killip class 1–4) | Killip class 1 (no congestive heart failure) | Killip class 2–3 (congestive heart failure) | Killip class 4 (cardiogenic shock) | |||||
|---|---|---|---|---|---|---|---|---|
| Group | MINAP (UK) N = 109 719) | JROAD‐DPC (Japan) N = 161 911) | MINAP (UK) N = 87 191) | JROAD‐DPC (Japan) N = 79 983) | MINAP (UK) N = 15 136) | JROAD‐DPC (Japan) N = 59 620) | MINAP (UK) N = 7392) | JROAD‐DPC (Japan) N = 22 308) |
| In‐hospital care | ||||||||
| pPCI (%) | 83 821 (76.7) | 135 214 (83.5) | 69 168 (79.6) | 68 950 (86.2) | 8768 (58.2) | 48 700 (81.7) | 5885 (79.9) | 17 564 (78.7) |
| Revascularization other than pPCI (including CABG surgery) (%) | 8295 (8.1) | 10 607 (6.6) | 6712 (8.1) | 4152 (5.2) | 1306 (10.1) | 4996 (8.4) | 277 (4.0) | 1459 (6.5) |
| Aspirin (%) | 106 906 (98.9) | 150 772 (93.3) | 85 670 (99.3) | 76 099 (95.3) | 14 448 (97.9) | 56 385 (94.7) | 6788 (96.1) | 18 288 (82.2) |
| P2Y12 inhibitor (%) | 99 640 (92.8) | 144 947 (89.7) | 80 633 (94.2) | 73 865 (92.6) | 13 317 (90.0) | 53 500 (89.9) | 5690 (81.6) | 17 552 (79.0) |
| ACE‐I/ARB (%) | 67 556 (71.5) | 112 952 (69.9) | 55 343 (73.5) | 59 023 (73.9) | 8854 (67.7) | 42 505 (71.4) | 3359 (55.2) | 11 424 (51.3) |
| Beta‐blocker (%) | 94 842 (90.2) | 99 395 (61.4) | 78 043 (92.5) | 49 440 (61.8) | 12 377 (86.2) | 38 843 (65.2) | 4422 (68.3) | 11112 (49.8) |
| Furosemide (%) | 18 199 (19.7) | 56 837 (35.2) | 8687 (11.8) | 16 794 (21.0) | 7475 (57.3) | 27 410 (46.0) | 2037 (34.0) | 12 633 (56.8) |
| MRA (%) | 13 986 (14.9) | 26 937 (16.7) | 9214 (12.4) | 7465 (9.4) | 3785 (28.5) | 13 851 (23.4) | 987 (16.2) | 5529 (24.9) |
| Echocardiography (%) | 77 890 (75.9) | 148 549 (91.8) | 62 112 (75.9) | 73 936 (92.6) | 10 955 (77.9) | 55 367 (93.3) | 4823 (72.1) | 18 892 (85.1) |
| Outcomes | ||||||||
| In‐hospital death (%) | 8095 (7.4) | 13 262 (8.2) | 2986 (3.4) | 1383 (1.7) | 2385 (15.8) | 3785 (6.4) | 2724 (36.9) | 8094 (36.3) |
| Length of hospital stay (days), mean (SD) | 5.0 (7.4) | 17.0 (14.4) | 4.3 (6.2) | 14.6 (9.7) | 8.3 (10.2) | 19.0 (15.1) | 6.7 (10.6) | 20.9 (22.4) |
| Prescription for survivors to discharge from hospital | MINAP (UK) N = 101 624) | JROAD‐DPC (Japan) N = 148 649) | MINAP (UK) N = 84 205) | JROAD‐DPC (Japan) N = 78 600) | MINAP (UK) N = 12 751) | JROAD‐DPC (Japan) N = 55 835) | MINAP (UK) N = 4668) | JROAD‐DPC (Japan) N = 14 214) |
| Aspirin (%) | 100 269 (99.5) | 143 592 (96.7) | 83 239 (99.5) | 75 892 (96.7) | 12 458 (99.0) | 54 050 (96.9) | 4572 (99.2) | 13 650 (96.1) |
| P2Y12 inhibitor (%) | 94 498 (94.7) | 137 974 (92.9) | 78 674 (95.0) | 73 501 (93.8) | 11 669 (93.0) | 51 370 (92.5) | 4155 (93.1) | 12 999 (91.8) |
| Statins (%) | 90 590 (90.8) | 125 352 (84.4) | 75 946 (91.6) | 67 584 (86.1) | 11 082 (88.2) | 46 408 (83.2) | 3562 (82.1) | 11 360 (80.0) |
| ACE‐I/ARB (%) | 65 615 (74.7) | 112 254 (75.6) | 54 540 (74.9) | 59 959 (76.4) | 8119 (73.2) | 42 033 (75.4) | 2956 (75.5) | 10 262 (72.3) |
| Beta‐blocker (%) | 92 066 (93.4) | 98 104 (66.0) | 76 864 (93.9) | 49 895 (63.5) | 11 309 (91.5) | 38 237 (68.5) | 3893 (89.6) | 9963 (70.3) |
| MRA (%) | 13 563 (15.6) | 25 475 (17.2) | 9102 (12.7) | 7430 (9.5) | 3568 (31.7) | 13 268 (23.8) | 893 (22.7) | 4777 (33.7) |
Abbreviations: UK, United Kingdom; ACE‐I/ARB, angiotensin angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; pPCI, primary percutaneous coronary intervention; GABG, coronary artery bypass grafting.